GSK heart drug disappoints

Investor's Business Daily

A heart drug GlaxoSmithKline (GSK) acquired when it bought Human Genome Sciences in Aug. '12 failed to lower the risk of heart attack in the 1st of 2 late-stage trials of the drug. Glaxo said darapladib was no better than a placebo at lowering the risk of a heart attack, stroke or death in more than 15,000 heart patients, which was the main goal. The U.K. drug company is still conducting late-stage trials to test its use in more than 13,000 patients who recently had a heart attack or stroke. Shares slipped 1.6% to 52.18.

View Comments (0)